CD34+ dendritic cell vaccine

The **CD34+ dendritic cell vaccine** is an investigational cell-based immunotherapy composed of dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells (HPCs), typically derived from peripheral blood or bone marrow[1][3]. These dendritic cells are loaded (pulsed) with tumor-associated antigens (often including peptides from melanoma antigens like MART-1/Melan A, gp100, tyrosinase, MAGE-3) to stimulate a patient’s immune system to generate antigen-specific T-cell responses targeting cancer cells[1][3]. In some protocols, dendritic cells may be genetically modified to further enhance immunogenicity[3]. Mechanistically, the vaccine acts as an **immunotherapeutic agent** by presenting selected antigens to both CD4+ and CD8+ T cells, thereby inducing specific immune responses (tumor-specific, viral peptide-specific, or generic immune responses)[1][3]. Clinical trials have primarily focused on late-stage melanoma[1], but broader cancer applications are under investigation[2][3].

Other names

CD34+ progenitor-derived dendritic cell vaccineCD34 HPC-derived DC vaccineCD-34 HPC-derived DC vaccineCD 34 HPC-derived DC vaccine